You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CART

Showing 1 - 25 of 1,050
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Decreasing On-Shift Stress With a Crisis Intervention Cart Trial in Dallas (Aromatherapy patches)

Recruiting
  • Decreasing On-Shift Stress With a Crisis Intervention Cart
  • Aromatherapy patches
  • Dallas, Texas
    Methodist Dallas Medical Center
Jul 6, 2023

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, Selinexor-VRD)

Recruiting
  • Multiple Myeloma
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 12, 2023

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 13, 2023

Prostate Cancer Trial in Beijing (CART-PSMA cells)

Recruiting
  • Prostate Cancer
  • CART-PSMA cells
  • Beijing, China
    Chinese PLA General Hospital
Dec 12, 2022

Solid Tumor Trial (HER2-E-CART cells)

Not yet recruiting
  • Solid Tumor
  • HER2-E-CART cells
  • (no location specified)
Feb 16, 2023

Blood Pressure, Hypertension, Hypotension Trial in Gyeonggi-do (CART-I plus)

Completed
  • Blood Pressure
  • +2 more
  • CART-I plus
  • Gyeonggi-do, Pangyo, Korea, Republic of
    Sky Labs
Feb 2, 2023

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

Multiple Myeloma Trial in Philadelphia (BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART

Active, not recruiting
  • Multiple Myeloma
  • BCMA CART + huCART19
  • +2 more
  • Philadelphia, Pennsylvania
    Univ. of Pennsylvania
Jul 11, 2022

Castrate-Resistant Prostate Cancer Trial in Shanghai (LIGHT-PSMA-CART cells)

Suspended
  • Castrate-Resistant Prostate Cancer
  • LIGHT-PSMA-CART cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Jan 25, 2023

Healthy Trial in Gyeonggi-do (CART-I plus)

Completed
  • Healthy
  • CART-I plus
  • Gyeonggi-do, Pangyo, Korea, Republic of
    Sky Labs
Jan 12, 2023

Leukemia, Lymphoma, Cardiotoxicity Trial in Philadelphia

Completed
  • Leukemia
  • +4 more
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Jan 19, 2023

    Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

    Not yet recruiting
    • Kidney Transplant
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Sep 20, 2023

    Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial (3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells)

    Not yet recruiting
    • Acute Myeloid Leukemia (AML)
    • Multiple Myeloma (MM)
    • 3x10(6) CART-38 cellls
    • +5 more
    • (no location specified)
    Jul 15, 2022

    Study for Patients Treat With WU-CART-007

    Enrolling by invitation
    • T-cell Acute Lymphoblastic Leukemia
    • T-cell Lymphoblastic Lymphoma
    • Genetic: WU-CART-007
    • Saint Louis, Missouri
      Washington University
    Aug 18, 2022

    Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

    Not yet recruiting
    • Leukemia, Myeloid, Acute
    • CD33KO-HSPC; CART33
    • (no location specified)
    Jul 13, 2023

    Multiple Myeloma Trial in Boston, Milwaukee (CART-ddBCMA)

    Not yet recruiting
    • Multiple Myeloma
    • CART-ddBCMA
    • Boston, Massachusetts
    • +1 more
    Jul 7, 2022

    Pancreatic Cancer Trial in Shanghai (U87 CAR-T)

    Recruiting
    • Pancreatic Cancer
    • U87 CAR-T
    • Shanghai, China
      China Shanghai 10th People's Hospital
    Oct 29, 2022

    B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

    Active, not recruiting
    • B-cell Lymphoma
    • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Zhejiang University School of Med
    Sep 28, 2022

    Hyperemesis Gravidarum, Pregnancy Related Trial in Siirt (Blood sample)

    Completed
    • Hyperemesis Gravidarum
    • Pregnancy Related
    • Blood sample
    • Siirt, Turkey
      Siirt Üniversity Medical Faculty
    Jan 31, 2023

    Refractory HIV Associated Kaposi Sarcoma Trial (Dostarlimab in Combination Antiretroviral Therapy)

    Not yet recruiting
    • Refractory HIV Associated Kaposi Sarcoma
    • Dostarlimab in Combination Antiretroviral Therapy
    • (no location specified)
    Dec 2, 2022

    B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • B Lineage Lymphoblastic Lymphoma
    • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
    • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
    • Philadelphia, Pennsylvania
      Children's Hospital of Philadelphia
    Jan 25, 2023

    Multiple Myeloma Trial in Zhengzhou (PD1-BCMA-CART)

    Not yet recruiting
    • Multiple Myeloma
    • PD1-BCMA-CART
    • Zhengzhou, Henan, China
      First Affliated Hospital of Zhengzhou University
    May 15, 2022

    B-All, Acute Lymphoblastic Leukemia Trial run by the National Cancer Institute (NCI) (NGS testing)

    Not yet recruiting
    • B-All
    • Acute Lymphoblastic Leukemia
    • NGS testing
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    CART Treatment, B Cell Lymphoma Trial in Tel-Aviv (Eltrombopag)

    Recruiting
    • CART Treatment
    • B Cell Lymphoma
    • Tel-Aviv, Israel
      Tel-Aviv Sourasky Medicak center / BMT Unit
    Apr 14, 2022

    Prostate Cancer Trial in Philadelphia (CART-PSMA-TGFßRDN cells, Cyclophosphamide, Fludarabine)

    Recruiting
    • Prostate Cancer
    • CART-PSMA-TGFβRDN cells
    • +2 more
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Mar 17, 2022